Exploring the role of insulin-like growth factor binding protein-1 in identifying idiopathic multicentric Castleman's disease types Implications for the mTOR signaling pathway

Exploring the role of insulin-like growth factor binding protein-1 in identifying idiopathic multicentric Castleman's disease types : Implications for the mTOR signaling pathway

Copyright © 2023 Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 256(2023) vom: 29. Nov., Seite 109798
1. Verfasser: Sumiyoshi, Remi (VerfasserIn)
Weitere Verfasser: Koga, Tomohiro, Fukui, Shoichi, Furukawa, Kaori, Momoki, Mamiko, Ichinose, Kunihiro, Yano, Shingo, Kawakami, Atsushi
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2023
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Research Support, Non-U.S. Gov't IGFBP-1 RNA sequencing iMCD-NOS iMCD-TAFRO mTOR Insulin-Like Growth Factor Binding Protein 1 TOR Serine-Threonine Kinases EC 2.7.11.1
Beschreibung
Zusammenfassung:Copyright © 2023 Elsevier Inc. All rights reserved.
OBJECTIVE: To determine the molecular differences between iMCD-thrombocytopenia, anasarca, fevers, reticulin myelofibrosis, organomegaly (TAFRO), and iMCD-not otherwise specified (NOS)
METHODS: CD4-positive T cells were isolated from two iMCD-TAFRO and two iMCD-NOS patients for RNA sequencing comparison. Serum proteins of two iMCD-TAFRO and four iMCD-NOS patients were comprehensively analyzed to identify pathogenesis-associated proteins. IGFBP-1 protein, extracted from serum analysis, was compared to healthy controls, iMCD, systemic lupus erythematosus, and rheumatoid arthritis patients
RESULTS: RNA sequencing of CD4-positive T cells revealed enhanced mTOR-related signaling in iMCD-TAFRO compared to iMCD-NOS. Comprehensive serum analysis found IGFBP-1 linked to iMCD pathogenesis, significantly higher in iMCD-TAFRO. This protein may be elevated in patients with iMCD caused by an enhanced mTOR pathway
CONCLUSION: The mTOR pathway is suggested to be activated in iMCD-TAFRO compared to iMCD-NOS, which may elevate the protein IGFBP-1. This protein may be a biomarker to distinguish iMCD-TAFRO from iMCD-NOS
Beschreibung:Date Completed 06.11.2023
Date Revised 06.11.2023
published: Print-Electronic
Citation Status MEDLINE
ISSN:1521-7035
DOI:10.1016/j.clim.2023.109798